Voyager Therapeutics partnered with Novartis in a potential $1.7 billion deal. The collaboration will enable Novartis to use the gene therapy company’s capsid discovery platform to create new treatments for three undisclosed CNS targets.
At WORLDSymposium, Astellas Pharma presented interim safety data from a Phase I/II study assessing the company’s AAV gene therapy for the rare, autosomal metabolic disease Pompe disease.
Shares of LogicBio Therapeutics fell more than 57 percent on February 2 after the company announced that its gene therapy for pediatric patients with methylmalonic acidemia was placed on clinical hold by the U.S. Food and Drug Administration.
Cambridge, Mass.-based Voyager Therapeutics entered a deal allowing Pfizer to exercise options to license novel capsids for gene therapies.
Novartis is expanding the Swiss pharma giant’s optogenetics portfolio with the acquisition of gene therapy company Arctos Medical.
Swiss pharma giant Roche announced a partnership with Shape Therapeutics valued at more than $3 billion that will attempt to harness the Seattle-based company’s RNA editing platform to take on neurodegenerative diseases as well as others.
Shape Therapeutics generated $112 million from a recent Series B financing round the Seattle biotechnology firm co-led with Decheng Capital and Breton Capital.
Working through two subsidiaries, life sciences giant Bayer is taking multiple shots at Parkinson’s disease. In addition to Bayer’s efforts to tackle Parkinson’s, Adhera Therapeutics announced that the company will acquire a new class of drug aimed at the disease.
Biogen reported that the company’s gene therapy, cotoretigene toliparvovec, failed to hit the primary endpoint of the Phase II/III XIRIUS trial for X-linked retinitis pigmentosa (XLRP).
Biogen and Capsigen forged a strategic collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to become transformative gene therapies that treat underlying genetic causes of various central nervous system and neuromuscular disorders.